- Lars Rebien Sørensen elected as chair and Cees de Jong as vice chair until March 26, 2026.
- Board members Britt Meelby Jensen and Stephan Engels newly elected.
- Helge Lund, Henrik Poulsen, and others stepped down from the board.
- Board committees restructured with new appointments.
Board Changes
At the Extraordinary General Meeting held on November 14, 2025, Novo Nordisk A/S elected new members to its Board of Directors. Lars Rebien Sørensen was appointed as the chair, and Cees de Jong as the vice chair. Britt Meelby Jensen and Stephan Engels were also elected as board members. These appointments are effective until the next Annual General Meeting on March 26, 2026.
Departures
Several board members, including Helge Lund, Henrik Poulsen, Laurence Debroux, Andreas Fibig, Sylvie Grégoire, Christina Law, and Martin Mackay, stepped down from their positions.
Board Committees
The Board of Directors restructured its committees following the meeting. Lars Rebien Sørensen will chair the People and Governance Committee. Cees de Jong will chair the Remuneration Committee and serve on the Audit Committee. Stephan Engels will chair the Audit Committee and serve on the Remuneration and People and Governance Committees. Other committee members include Elisabeth Dahl Christensen, Liselotte Hyveled, Mette Bøjer Jensen, Britt Meelby Jensen, Kasim Kutay, and Thomas Rantzau.
Chair's Statement
Lars Rebien Sørensen emphasized his mandate to support the CEO and management in their transformation plans to regain competitive leadership and to prepare for his successor. He also expressed his commitment to engaging with minority shareholders to understand their views.
